Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia.

Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebti S, Malafa MP.

EBioMedicine. 2015 Nov 14;2(12):1987-95. doi: 10.1016/j.ebiom.2015.11.025. eCollection 2015 Dec.

2.

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.

Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E, Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM.

Cancer Med. 2016 Feb;5(2):294-303. doi: 10.1002/cam4.598. Epub 2015 Dec 29.

3.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A.

Cancer Chemother Pharmacol. 2012 Oct;70(4):567-74. Epub 2012 Aug 10.

4.

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.

Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM.

Clin Cancer Res. 2011 Dec 15;17(24):7743-53. doi: 10.1158/1078-0432.CCR-11-1540. Epub 2011 Oct 25.

5.

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM.

J Clin Oncol. 2011 Jun 10;29(17):2350-6. doi: 10.1200/JCO.2010.33.9432. Epub 2011 Apr 25.

6.

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM.

Invest New Drugs. 2011 Dec;29(6):1381-9. doi: 10.1007/s10637-010-9479-2. Epub 2010 Jul 20.

7.

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI.

Cancer Res. 2006 Sep 15;66(18):9299-307.

8.

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN.

Mol Cancer Ther. 2006 Aug;5(8):2130-7.

9.

Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2006 Jan 15;12(2):523-8.

10.

The absolute bioavailability of oral vinorelbine in patients with solid tumors.

Lush RM, McCune JS, Tetteh L, Thompson JA, Mahany JJ, Garland L, Suttle AB, Sullivan DM.

Cancer Chemother Pharmacol. 2005 Dec;56(6):578-84. Epub 2005 Jul 7.

PMID:
16001165
11.

Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.

Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2005 May 1;11(9):3335-41.

12.

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD.

Ann Pharmacother. 2003 Oct;37(10):1369-74.

PMID:
14519054
13.

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM.

J Clin Oncol. 2001 Apr 15;19(8):2319-33.

PMID:
11304786
14.
15.
16.

A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.

Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, Figg WD, Sausville EA.

Urol Int. 1999;63(2):120-5.

PMID:
10592501
17.
18.

Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.

Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD.

J Clin Pharmacol. 1999 Apr;39(4):394-401.

PMID:
10197298
19.

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA.

J Clin Oncol. 1998 Sep;16(9):2986-99.

PMID:
9738567
20.

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D.

Tumori. 1998 Jan-Feb;84(1):87-9.

PMID:
9619724
21.

Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.

Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, Figg WD.

J Investig Med. 1998 Feb;46(2):66-72.

PMID:
9549229
22.

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.

Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe ES, Sausville EA.

Ann Intern Med. 1997 Jun 1;126(11):882-5. No abstract available.

PMID:
9163289
23.

Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.

Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, Figg WD.

Pharmacotherapy. 1997 May-Jun;17(3):431-7.

PMID:
9165547
24.

Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.

Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR.

Cancer J Sci Am. 1997 May-Jun;3(3):174-9.

PMID:
9161783
25.

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.

Dixon SC, Zalles A, Giordano C, Lush RM, Venzon D, Reed E, Figg WD.

Cancer Lett. 1997 Feb 26;113(1-2):111-6.

PMID:
9065809
26.

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.

Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD.

J Clin Pharmacol. 1997 Feb;37(2):123-8.

PMID:
9055138
27.

The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.

Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R.

Pharmacotherapy. 1997 Jan-Feb;17(1):91-7.

PMID:
9017768
28.

Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.

Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD.

Ann Pharmacother. 1997 Jan;31(1):76-82. Review.

PMID:
8997471
29.

Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.

Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD.

Ther Drug Monit. 1996 Dec;18(6):714-20.

PMID:
8946671
30.

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.

Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR.

Ann Oncol. 1996 Nov;7(9):939-44.

PMID:
9006745
31.

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES.

Blood. 1996 Aug 15;88(4):1188-97.

32.

Suramin-induced neutropenia.

Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, Figg WD.

Eur J Cancer. 1996 Aug;32A(9):1534-9.

PMID:
8911114
33.

The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.

Middleman MN, Lush RM, Figg WD.

Pharmacotherapy. 1996 May-Jun;16(3):376-81.

PMID:
8726595
34.

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.

Middleman MN, Lush RM, Sartor O, Reed E, Figg WD.

Cancer Treat Rev. 1996 Mar;22(2):105-18. Review. No abstract available.

PMID:
8665563
35.

Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.

Figg WD, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SH, Tompkins A, Reed E, Sartor O.

Acta Oncol. 1996;35(6):763-5. No abstract available.

PMID:
8938230
36.

Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women.

Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO 3rd.

Am J Cardiol. 1995 Nov 15;76(14):1072-3.

PMID:
7484866
37.

Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.

Kroboth PD, Folan MM, Lush RM, Chaikin PC, Shukla UA, Barbhaiya R, Salazar DE.

J Clin Psychopharmacol. 1995 Oct;15(5):306-19.

PMID:
8830061
38.
39.
40.

Hepatic CT enhancement: comparison of ionic and nonionic contrast agents in the same patients.

Chambers TP, Baron RL, Lush RM, Dodd GD 3rd, Miller WJ.

Radiology. 1994 Mar;190(3):721-5.

PMID:
8115618
41.

Hepatic CT enhancement: a method to demonstrate reproducibility.

Chambers TP, Baron RL, Lush RM, Dodd GD 3rd, Miller WJ, Confer SR.

Radiology. 1993 Sep;188(3):627-31.

PMID:
8351324
42.

Container residue after the administration of aqueous activated charcoal products.

Krenzelok EP, Lush RM.

Am J Emerg Med. 1991 Mar;9(2):144-6.

PMID:
1994942

Supplemental Content

Support Center